title: Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists.
abstract: OBJECTIVE
  To describe the psychiatric indications of neuroleptics (especially the relative share of schizophrenic and other psychotic disorders) and the usage patterns of these drugs (dose, duration, coprescriptions).
  
  
  METHODS
  A one-day national cross-sectional survey in a random sample of 723 French psychiatrists was carried out in 1996. Each psychiatrist was asked to complete a standardized questionnaire for the first three patients seen the day of the survey to whom at least one neuroleptic was prescribed (initiated or renewed).
  
  
  RESULTS
  One thousand seven hundred and fifty-four questionnaires were returned. Three quarters of the patients (74%) were psychotic (664 with schizophrenia, and 636 other psychosis), 19. 3% were depressive and 6.7% had other psychiatric disorders. Phenothiazines were the most often prescribed (40.8%), followed by butyrophenones (22.5%), benzamides (15.8%), other neuroleptics (14. 8%) and thioxanthenes (6.1%). Among schizophrenic subjects, an average number of 1.54 (95% CI: 1.50-1.60) neuroleptics were prescribed per patient, compared with 1.4 (95% CI: 1.32-1.41) and 1. 2 (95% CI: 1.14-1.23) in other psychotic and depressive subjects, respectively. Regardless of the indication, non-neuroleptic psychotropic drugs were coprescribed in 75.4%, mainly benzodiazepines (75.7%). Adjuvant drugs used in prevention or treatment of side-effects were coprescribed in 46.7%, mostly anticholinergic antiparkinsonians (86.1%).
  
  
  CONCLUSIONS
  Neuroleptics are mainly prescribed for psychotic disorders and especially schizophrenia. However, current recommendations are not always followed.
authors.affiliation: Department of Pharmacology, Victor Segalen Bordeaux 2 University, Bordeaux, France. Annie.Fourrier@pharmaco.u-bordeaux2.fr
authors.forename: A
authors.initials: A
authors.lastname: Fourrier
authors.forename: I
authors.initials: I
authors.lastname: Gasquet
authors.forename: M P
authors.initials: MP
authors.lastname: Allicar
authors.forename: M
authors.initials: M
authors.lastname: Bouhassira
authors.forename: J P
authors.initials: JP
authors.lastname: Lépine
authors.forename: B
authors.initials: B
authors.lastname: Bégaud
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D003625:Data Collection; D003627:Data Interpretation, Statistical; D011307:Drug Prescriptions; D004359:Drug Therapy, Combination; D004363:Drug Utilization; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011153:Population; D011570:Psychiatry; D011618:Psychotic Disorders / Q000188:drug therapy / Q000453:epidemiology; D012559:Schizophrenia / Q000188:drug therapy / Q000453:epidemiology; D011795:Surveys and Questionnaires
chemical_list: D014150:Antipsychotic Agents